Research to take place at Johns Hopkins, New York University and University of Alabama Birmingham DENVER, Oct. 05, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biopharmaceutical company focused on the treatment of mental health disorders and addiction, today announced that it plans to supply its lead drug candidate…


Previous articlePT265 – Jessica Cadoch, MA – Cooperation, Drug Exceptionalism, and 12-step Programs
Next articleAnima Mundi: Psychedelics and The Ensouled Earth